“We had 2 main goals with this round of the guidelines,” said Mary B. Daly, PhD, FACP, of the Fox Chase Cancer Center in Philadelphia, who also serves as the chair of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. “One, of course was to keep up to date with the evidence as it continues to emerge so that it can inform the guidelines we write. Read more . . .